Advertisement
Advertisement
U.S. markets open in 3 hours 35 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.60+0.75 (+2.69%)
At close: 04:00PM EDT
29.50 +0.90 (+3.15%)
After hours: 06:30PM EDT
Advertisement

Vir Biotechnology, Inc.

499 Illinois Street
Suite 500
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees444

Key Executives

NameTitlePayExercisedYear Born
Dr. George A. Scangos Ph.D.Pres, CEO & Director1.07MN/A1948
Mr. Howard HornExec. VP, CFO & Sec.732.41kN/A1978
Dr. Ann M. Hanly Ph.D.Exec. VP & Chief Technology Officer922.22kN/A1970
Dr. Herbert W. Virgin IV, M.D., Ph.D.Exec. VP of Research & Chief Scientific Officer1.12M9.49M1956
Dr. Phillip Pang M.D., Ph.D.Exec. VP & Chief Medical Officer780.46k3.66M1975
Dr. Klaus Frueh Ph.D.Co-Founder & Scientific AdvisorN/AN/A1960
Dr. Lawrence CoreyCo-Founder & Scientific AdvisorN/AN/AN/A
Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorN/AN/AN/A
Ms. Johanna Friedl-NadererExec. VP & COON/AN/A1968
Mr. Steven J. RiceExec. VP & Chief Admin. OfficerN/AN/A1960
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Corporate Governance

Vir Biotechnology, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement